Cargando…

Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine

Vaccine is the main public health measure to reduce SARS-CoV-2 transmission and hospitalization, and a massive scientific effort worldwide resulted in the rapid development of effective vaccines. This work aimed to define the dynamics and persistence of humoral and cell-mediated immune response in H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Agrati, Chiara, Castilletti, Concetta, Goletti, Delia, Sacchi, Alessandra, Bordoni, Veronica, Mariotti, Davide, Notari, Stefania, Matusali, Giulia, Meschi, Silvia, Petrone, Linda, Aiello, Alessandra, Najafi Fard, Saeid, Farroni, Chiara, Colavita, Francesca, Lapa, Daniele, Leone, Sara, Agresta, Alessandro, Capobianchi, Maria, Ippolito, Giuseppe, Vaia, Francesco, Puro, Vincenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034067/ https://www.ncbi.nlm.nih.gov/pubmed/35461335 http://dx.doi.org/10.1038/s41598-022-07741-z

Ejemplares similares

Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine
por: Agrati, Chiara, et al.
Publicado: (2021)

Impact of Prior Influenza and Pneumoccocal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination
por: Puro, Vincenzo, et al.
Publicado: (2021)

Immunogenicity and safety of BNT162b2 COVID‐19 vaccine in a chronic lymphocytic leukaemia patient
por: Agrati, Chiara, et al.
Publicado: (2021)

Differential Dynamics of SARS-CoV-2 Binding and Functional Antibodies upon BNT162b2 Vaccine: A 6-Month Follow-Up
por: Matusali, Giulia, et al.
Publicado: (2022)

SARS-CoV-2 Breakthrough Infections According to the Immune Response Elicited after mRNA Third Dose Vaccination in COVID-19-Naïve Hospital Personnel
por: Santoro, Annapaola, et al.
Publicado: (2023)

Multi-omics approach to COVID-19: a domain-based literature review
por: Montaldo, Chiara, et al.
Publicado: (2021)

In Vitro Models for Studying Entry, Tissue Tropism, and Therapeutic Approaches of Highly Pathogenic Coronaviruses
por: Najafi Fard, Saeid, et al.
Publicado: (2021)

Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19
por: Agrati, Chiara, et al.
Publicado: (2021)

Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies
por: Tortorella, Carla, et al.
Publicado: (2022)

Virological and Serological Characterisation of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination Between December 2020 and March 2021
por: Colavita, Francesca, et al.
Publicado: (2022)

The interplay between SARS-CoV-2 infected airway epithelium and immune cells modulates regulatory/inflammatory signals
por: Bordoni, Veronica, et al.
Publicado: (2022)

Performance evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization test
por: Meschi, Silvia, et al.
Publicado: (2020)

Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis
por: Farroni, Chiara, et al.
Publicado: (2022)

ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients
por: Picchianti-Diamanti, Andrea, et al.
Publicado: (2021)

Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV
por: Vergori, Alessandra, et al.
Publicado: (2022)

Vδ2 T-Cells Kill ZIKV-Infected Cells by NKG2D-Mediated Cytotoxicity
por: Cimini, Eleonora, et al.
Publicado: (2019)

Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count
por: Antinori, Andrea, et al.
Publicado: (2022)

Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients
por: Aiello, Alessandra, et al.
Publicado: (2021)

SARS-CoV-2 Infection of Airway Epithelium Triggers Pulmonary Endothelial Cell Activation and Senescence Associated with Type I IFN Production
por: Bordoni, Veronica, et al.
Publicado: (2022)

PMN-MDSC Frequency Discriminates Active Versus Latent Tuberculosis and Could Play a Role in Counteracting the Immune-Mediated Lung Damage in Active Disease
por: Grassi, Germana, et al.
Publicado: (2021)

Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy
por: Alonzi, Tonino, et al.
Publicado: (2021)

Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies
por: Aiello, Alessandra, et al.
Publicado: (2023)

Initial immune response after exposure to Mycobacterium tuberculosis or to SARS-COV-2: similarities and differences
por: Aiello, Alessandra, et al.
Publicado: (2023)

SARS-CoV-2 Specific Immune Response and Inflammatory Profile in Advanced HIV-Infected Persons during a COVID-19 Outbreak
por: Vergori, Alessandra, et al.
Publicado: (2022)

The immune response as a double‐edged sword: The lesson learnt during the COVID‐19 pandemic
por: Agrati, Chiara, et al.
Publicado: (2022)

SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus
por: Matusali, Giulia, et al.
Publicado: (2021)

Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results
por: Agrati, Chiara, et al.
Publicado: (2022)

ZIKV Infection Induces an Inflammatory Response but Fails to Activate Types I, II, and III IFN Response in Human PBMC
por: Colavita, Francesca, et al.
Publicado: (2018)

Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis
por: Petrone, Linda, et al.
Publicado: (2022)

Evidences for lipid involvement in SARS-CoV-2 cytopathogenesis
por: Nardacci, Roberta, et al.
Publicado: (2021)

Myeloid-Derived Suppressor Cells in COVID-19: The Paradox of Good
por: Grassi, Germana, et al.
Publicado: (2022)

Tropism of the Chikungunya Virus
por: Matusali, Giulia, et al.
Publicado: (2019)

Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose
por: Ruggieri, Serena, et al.
Publicado: (2023)

Emerging viral infections in immunocompromised patients: A great challenge to better define the role of immune response
por: Agrati, Chiara, et al.
Publicado: (2023)

Functional CVIDs phenotype clusters identified by the integration of immune parameters after BNT162b2 boosters
por: Piano Mortari, Eva, et al.
Publicado: (2023)

Pleural Mesothelial Cells Modulate the Inflammatory/Profibrotic Response During SARS-CoV-2 Infection
por: Matusali, Giulia, et al.
Publicado: (2021)

Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach
por: D’Abramo, Alessandra, et al.
Publicado: (2021)

Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave
por: Aiello, Alessandra, et al.
Publicado: (2022)

Humoral and cellular responses to spike of δ SARS-CoV-2 variant in vaccinated patients with immune-mediated inflammatory diseases
por: Petrone, Linda, et al.
Publicado: (2022)

Proteomic analysis identifies the RNA helicase DDX3X as a host target against SARS-CoV-2 infection
por: Ciccosanti, Fabiola, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dak0hacmfpiqovhvtdtnerhtjo